Horizon Discovery (HZD) Given Average Recommendation of “Buy” by Analysts

Shares of Horizon Discovery (LON:HZD) have received a consensus recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is GBX 236 ($3.29).

HZD has been the topic of several research reports. Peel Hunt initiated coverage on shares of Horizon Discovery in a research note on Tuesday, March 20th. They set a “hold” rating and a GBX 181 ($2.52) price objective on the stock. Numis Securities reissued a “buy” rating and set a GBX 300 ($4.18) price objective on shares of Horizon Discovery in a research note on Tuesday, February 20th. Finally, N+1 Singer dropped their price objective on shares of Horizon Discovery from GBX 250 ($3.49) to GBX 230 ($3.21) and set a “buy” rating on the stock in a research note on Monday, February 19th.

In other news, insider Susan Galbraith bought 70,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were purchased at an average price of GBX 179 ($2.50) per share, for a total transaction of £125,300 ($174,755.93). Also, insider Jonathan Milner bought 370,000 shares of the company’s stock in a transaction dated Thursday, April 5th. The stock was purchased at an average price of GBX 132 ($1.84) per share, for a total transaction of £488,400 ($681,171.55). In the last quarter, insiders bought 834,492 shares of company stock worth $125,549,180.

LON:HZD remained flat at $GBX 157.50 ($2.20) during mid-day trading on Friday. 67,152 shares of the company traded hands, compared to its average volume of 258,981. Horizon Discovery has a 1-year low of GBX 160 ($2.23) and a 1-year high of GBX 294 ($4.10).

Horizon Discovery Company Profile

Horizon Discovery Group plc, a life science company, engages in precision gene editing to design, build, and apply cells to advance human health worldwide. Its core capabilities are built around its proprietary transnational genomics platform, a suite of gene editing tools, such as rAAV, ZFN, and CRISPR to alter gene sequence in human or mammalian cell-lines.

Analyst Recommendations for Horizon Discovery (LON:HZD)

Receive News & Ratings for Horizon Discovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Government Properties Income Trust  Lowered to Sell at Zacks Investment Research
Government Properties Income Trust Lowered to Sell at Zacks Investment Research
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Republic Services  Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Republic Services Share Price
Kyocera  Earning Somewhat Positive Media Coverage, Accern Reports
Kyocera Earning Somewhat Positive Media Coverage, Accern Reports
Energy Transfer Partners  Earning Somewhat Positive Press Coverage, Accern Reports
Energy Transfer Partners Earning Somewhat Positive Press Coverage, Accern Reports
Zacks: Middlefield Banc  Given Consensus Recommendation of “Strong Buy” by Brokerages
Zacks: Middlefield Banc Given Consensus Recommendation of “Strong Buy” by Brokerages
Starwood Property Trust  Given Consensus Recommendation of “Buy” by Brokerages
Starwood Property Trust Given Consensus Recommendation of “Buy” by Brokerages


© 2006-2018 Ticker Report. Google+.